Disc Medicine在第14届血液肿瘤学会（SOHO）年会上，公布了Restore-Pv二期临床试验的初步结果。这项研究聚焦于真性红细胞增多症（PV）患者群体。
该试验的初步数据已在会议期间正式对外展示。真性红细胞增多症作为一种骨髓增殖性肿瘤，长期以来困扰着临床治疗领域。Disc Medicine此次披露的研究成果，为这一适应症领域带来了新的临床观察视角。
值得注意的是，此次公布的内容属于试验的初步分析结果。完整的数据解读和后续随访结果，预计将在未来的医学会议或同行评审期刊中进一步呈现。业界对该药物的作用机制及其在PV患者中的潜在应用价值，保持着持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.